Skip to main content
logo
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
6.77
+0.02 (0.30%)
Oct 7, 2026, 10:33 AM EDT - Market open

Cartesian Therapeutics Revenue

Cartesian Therapeutics had revenue of $1.48M in the twelve months ending June 30, 2026, up 43.96% year-over-year. In the year 2025, Cartesian Therapeutics had annual revenue of $2.80M, down -92.81%.

Revenue (ttm)
$1.48M
Revenue Growth
+43.96%
P/S Ratio
138.27
Revenue / Employee
$19,693
Employees
75
Market Cap
204.83M

Revenue Chart

Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20252.80M-36.12M-92.81%
Dec 31, 202438.91M12.91M49.64%
Dec 31, 202326.00M-84.77M-76.53%
Dec 31, 2022110.78M25.70M30.21%
Dec 31, 202185.08M68.48M412.60%
Dec 31, 202016.60M9.92M148.57%
Dec 31, 20196.68M5.77M639.42%
Dec 31, 2018903.00K696.00K336.23%
Dec 31, 2017207.00K-7.88M-97.44%
Dec 31, 20168.08M2.07M34.47%
Dec 31, 20156.01M2.97M97.73%
Dec 31, 20143.04M1.56M105.54%
Dec 31, 20131.48M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Protalix BioTherapeutics80.62M
Compugen74.00M
Alpha Cognition15.26M
Keros Therapeutics15.01M
Alector13.86M
Lineage Cell Therapeutics13.08M
Whitehawk Therapeutics7.15M
Lyell Immunopharma27.00K
Revenue Rankings

RNAC News

More News